{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.03","value":"60.1"},{"groupId":"OG001","spread":"20.35","value":"55.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"57"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.10","value":"51.4"},{"groupId":"OG001","spread":"20.28","value":"47.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.92","value":"51.1"},{"groupId":"OG001","spread":"21.72","value":"42.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.16","value":"47.3"},{"groupId":"OG001","spread":"16.66","value":"35.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.96","value":"43.2"},{"groupId":"OG001","spread":"18.81","value":"35.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"title":"Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.72","value":"43.5"},{"groupId":"OG001","spread":"19.02","value":"36.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.67","value":"45.5"},{"groupId":"OG001","spread":"18.66","value":"37.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.45","value":"42.7"},{"groupId":"OG001","spread":"19.29","value":"36.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Cycle 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.42","value":"47.1"},{"groupId":"OG001","spread":"15.79","value":"35.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.11","value":"46.8"},{"groupId":"OG001","spread":"21.17","value":"47.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Cycle 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.04","value":"46.7"},{"groupId":"OG001","spread":"19.44","value":"48.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Cycle 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.52","value":"37.7"},{"groupId":"OG001","spread":"21.93","value":"45.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Cycle 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"description":"Skindex-29 was a self-administered 29-item dermatology patient-reported outcome measure that explores the domains of Functioning, Emotions and Symptoms. Data from the Skindex-29 came from the \"Dermatology Survey\" page. Scoring of the Skindex-29 was performed as per the developers' scoring algorithms. The score for each dimension was found by adding responses of 1 to 5 for each question, with higher scores indicating worse quality of life. The Skindex-29 yields three scale scores that assess physical symptoms scores range from 29 to 116, with higher scores indicating worse health-related quality of life. Average sub-scores for emotions, physical symptoms, and functioning was displayed.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG000","title":"Bexarotene Exposed"},{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG001","title":"Bexarotene Naive"}],"paramType":"MEAN","populationDescription":"The analysis was performed in FAS population was defined according to the intention-to-treat principle. This population included all participants enrolled into the study.","reportingStatus":"POSTED","timeFrame":"Baseline up to Cycle 12, an average of 12 months","title":"Skindex-29 Measurements of Average Sub-scores for Physical Symptoms From Baseline up to Cycle 12","type":"SECONDARY","unitOfMeasure":"score on a scale"}